Islam Mozaffarul, Datta Jharna, Lang James C, Teknos Theodoros N
Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, USA; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Oral Oncol. 2014 May;50(5):448-56. doi: 10.1016/j.oraloncology.2014.01.014. Epub 2014 Feb 22.
RhoC a pro-metastatic oncogene is constitutively active in many head and neck squamous cell carcinomas. MicroRNA-138 which possesses a documented tumor suppressor function can bind to the 3'UTR of RhoC mRNA and inhibit its activity. We hypothesize that miR-138 can inhibit the function of RhoC and consequently the activation of downstream target molecules involve in the signaling cascade. For this reason we investigated the role of miR-138 in HNSCC.
In vitro studies were carried out to evaluate the role of miR-138 in HNSCC cell lines and in primary tumors obtained from HNSCC patients. Real time RT-PCR, Western blot, cell motility, invasion and colony formation assays were performed according to standard procedures.
Data obtained by G-LISA and real time PCR shows an inverse correlation between RhoC expression and miR-138 in HNSCC cell lines. Additionally, we obtained a similar pattern of RhoC and miR-138 expression in primary tumors from HNSCC patients. Over expression of miR-138 in HNSCC lines showed down regulation of RhoC, as well as a decrease in cell motility, invasion colony and stress fiber formation. Furthermore, a significant down regulation was observed for FAK, Src and Erk(1/2) upon miR-138 overexpression.
These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk(1/2) by miR-138 overexpression is due to inhibition of RhoC in HNSCC.
RhoC是一种促转移癌基因,在许多头颈部鳞状细胞癌中持续激活。具有肿瘤抑制功能的微小RNA-138可与RhoC mRNA的3'非翻译区结合并抑制其活性。我们假设miR-138可抑制RhoC的功能,进而抑制参与信号级联反应的下游靶分子的激活。因此,我们研究了miR-138在头颈部鳞状细胞癌中的作用。
进行体外研究以评估miR-138在头颈部鳞状细胞癌细胞系和从患者获取的原发性肿瘤中的作用。按照标准程序进行实时逆转录聚合酶链反应、蛋白质免疫印迹、细胞运动、侵袭和集落形成测定。
通过G-LISA和实时聚合酶链反应获得的数据显示,头颈部鳞状细胞癌细胞系中RhoC表达与miR-138呈负相关。此外,我们在头颈部鳞状细胞癌患者的原发性肿瘤中获得了类似的RhoC和miR-138表达模式。头颈部鳞状细胞癌细胞系中miR-138的过表达显示RhoC下调,以及细胞运动、侵袭集落和应力纤维形成减少。此外,miR-138过表达后,粘着斑激酶、Src和细胞外信号调节激酶(1/2)显著下调。
这些发现强烈表明,通过过表达miR-138可抑制RhoC,这进一步减弱了导致癌症进展和存活的下游信号级联反应。此外,本研究首次表明,miR-138过表达导致粘着斑激酶、Src和细胞外信号调节激酶(1/2)下调是由于头颈部鳞状细胞癌中RhoC受到抑制。